Tirzepatide Results, Explained: What the SURMOUNT Trials Actually Show

Fifteen percent. Nineteen and a half. Just under twenty-one. Those are the three numbers that actually came out of the trial that got tirzepatide approved for weight loss — each one tied to a specific maintenance dose, not a transformation photo with no context attached. If you're deciding whether to start, or trying to figure out whether your first six weeks on it are normal, those numbers matter more than any before-and-after post you'll find, and so does the slower, less photogenic timeline behind them.

How much weight do people actually lose on tirzepatide, on average?

SURMOUNT-1, the trial behind tirzepatide's weight-management approval, is still the clearest source for what to expect. Over 72 weeks, adults without diabetes lost an average of about 15% of starting body weight on the 5mg maintenance dose, about 19.5% on 10mg, and close to 21% on the maximum 15mg dose — against roughly 3% on placebo. Those figures include everyone assigned to a dose, even people who didn't tolerate it well or stopped early, so they're a genuinely conservative read of what someone who stays on the medication and reaches that dose tends to see.

An average also hides a real spread. In the same trial, the large majority of people on the 5mg dose and nearly everyone on the 10mg or 15mg doses lost at least 5% of their weight — the threshold generally used to call a weight-loss drug 'working' — against a much smaller share on placebo. On the higher end, different analyses of SURMOUNT-1 put roughly a third to nearly 40% of people on the 10mg or 15mg doses crossing 25% or more, a result placebo essentially didn't produce. If your own number lands under the headline average, you're not necessarily a non-responder; you're somewhere in a distribution most coverage never shows you.

How long does it actually take for tirzepatide to start working?

Onset happens in two stages, and they don't happen at the same time. Appetite is usually first — food noise quiets, and portions that used to feel too small start feeling like enough — often within the first couple of weeks, well before the scale moves much. The scale lags behind on purpose, because tirzepatide starts at a deliberately low, sub-therapeutic 2.5mg dose meant for adjustment, not results.

A 2025 post hoc analysis of SURMOUNT-1 sorted participants by how fast the scale actually responded: about 82% had lost at least 5% of their weight by week 12 — three months in — and were classified as early responders. The remaining 18%, the 'late responders,' hadn't hit that mark by three months, but nine in ten of them went on to reach it by the end of the trial at 72 weeks, taking an average of roughly 25 weeks, or about six months, to get there. A slow first three months is common and doesn't predict failure; it usually means more time, not a different drug.

What does a realistic month-by-month timeline look like — 1, 3, 6, 12 months?

Knowing the shape of the curve ahead of time makes the slow early stretch easier to sit through. The timeline below tracks the dose climbing roughly every four weeks, not a fixed calendar — extending any step for tolerability pushes everything out.

• Weeks 1–4, 2.5mg starting dose: appetite is usually the first thing to shift while the scale barely moves — this dose exists to let your body adjust, not to treat anything yet.
• Month 3, week 12: the checkpoint tirzepatide research actually tracks. By here, about 82% of people are already down at least 5% of their starting weight; most of the remaining 18% catch up over the following months rather than staying stuck.
• Month 6: most people are still climbing the dose ladder around here — reaching 15mg takes at least five months — so the scale is usually still moving. Trial data on time-to-plateau runs from about six months for people who started at a lower BMI up to about nine months for a higher one.
• Month 12–18, roughly 72 weeks: this is where SURMOUNT-1 measured its headline numbers — about 15% at the 5mg dose, about 19.5% at 10mg, and close to 21% at 15mg.
• Beyond 18 months: loss tends to hold rather than keep climbing. In SURMOUNT-1's own three-year extension, average loss at week 176 was barely different from week 72 — about 15.4%, 19.9%, and 22.9% at those same three doses — evidence of a plateau, not the drug losing its grip.

What do real before-and-after numbers show — not transformation photos?

Strip away the marketing, and 'before and after' really means three response bands, each represented by real trial participants. A minority land under 5% loss and are generally considered non-responders — a rate that also shows up on placebo through the ordinary noise of diet and metabolism. Most people land in a moderate band, somewhere between 5% and 15% of body weight. And a meaningful share — roughly a third to nearly 40% of people at the 10mg or 15mg dose, depending on which SURMOUNT-1 analysis you're reading — cross 25% or more and would be called super-responders.

None of these bands is a verdict on effort. Response depends heavily on the dose actually reached, on genetics and receptor sensitivity that don't show up on an intake form, and on how consistently the weekly shot goes in. A photo online can't show you any of that. A number attached to a specific week and dose can.

How does tirzepatide actually work for weight loss?

Tirzepatide is a dual GIP and GLP-1 receptor agonist — built to activate two separate gut-hormone pathways at once, rather than the single pathway older GLP-1 medications target. The GLP-1 side does the more familiar work: it quiets appetite signals in the brain, slows how quickly the stomach empties so a normal meal feels filling for longer, and prompts the pancreas to release insulin only when blood sugar is actually elevated. GIP, the second hormone, appears to compound that effect on appetite and blood sugar handling, though researchers are still working out exactly how much of tirzepatide's larger average results comes from that second receptor versus the specific doses tested in its trials.

In practice, the appetite effect is doing most of the visible work. Less hunger and earlier fullness are why the scale moves without anyone white-knuckling a restrictive diet — the mechanism is hormonal, not willpower.

Zepbound vs. Mounjaro — does the brand change your results?

No, not because of the brand name itself. Zepbound and Mounjaro are the identical molecule, tirzepatide, made by the same manufacturer, using the same starting dose, the same 2.5mg titration steps, and the same 15mg ceiling — the full dosing chart covers that ladder step by step. What differs is the FDA approval each brand carries and the trial each one leans on: Zepbound was approved in November 2023 specifically for chronic weight management, built on SURMOUNT-1's results; Mounjaro was approved back in May 2022 for type 2 diabetes, built on the separate SURPASS trials, where dosing is guided by blood-sugar control rather than a weight target.

A prescriber can write either one off-label for weight loss, and the molecule in the pen doesn't know which name is on the box. What the brand actually changes is insurance and cost, not physiology — Zepbound's on-label status gives it a more direct path to weight-loss coverage and to the manufacturer's own savings programs, while Mounjaro used off-label for weight loss typically depends on a diabetes diagnosis to get anywhere with insurance.

Why might your results look different at 45+, in perimenopause?

This is the piece most tirzepatide coverage skips, and it's actually been studied directly. A 2025 post hoc analysis of the SURMOUNT trials, published in the journal Obesity, split women by reproductive stage — premenopausal, perimenopausal, and postmenopausal — and compared their results. Premenopausal women lost an average of about 26% of body weight on tirzepatide against about 2% on placebo. Perimenopausal and postmenopausal women lost about 23% against roughly 3% on placebo. Across every reproductive-stage group, the large majority — 97% to 98% — lost at least 5% of their weight on tirzepatide, compared with under a third on placebo.

Read that gap for what it actually is: real, but a few percentage points, not a different drug response. Falling estrogen is the likely driver — it shifts fat toward the abdomen and works against insulin sensitivity, adding friction to the same appetite and metabolic pathways tirzepatide is acting on. The medication is still clearly working in a 40-plus body. The data shows it's working against a bit more resistance, not that it's failing.

There's a second, separate piece worth flagging while you're sizing up your own numbers against the trial data: fast weight loss on any GLP-1 includes some lean muscle, not only fat, and that matters more after 40 because estrogen decline is already chipping away at the same tissue. Our guide to GLP-1 and muscle loss in perimenopause covers what protects your strength while the weight comes off — worth reading alongside these numbers, not instead of them.

What actually determines your individual result?

Trial averages explain the shape of the curve. They don't predict your specific number. A handful of factors reliably move the needle in real practice:

• The dose you actually reach and tolerate: SURMOUNT-1's own numbers show several points of gap between the 5mg and 15mg groups — reaching and staying on a higher maintenance dose, if your prescriber and your side effects allow it, generally means more loss.
• How consistently you take it: a missed or delayed weekly shot interrupts the steady drug level these medications depend on — consistency is a variable the trials controlled for that real life doesn't.
• Where you started: starting weight and metabolic health shape both how much percentage loss is realistic and how your body responds along the way — that's biology, not a personal shortfall.
• Whether you hit the 'working' threshold within three months: losing at least 5% by then is the checkpoint the trial data itself tracks; falling well short of it is usually the point a dose change gets discussed, not a reason to wait it out indefinitely.
• Individual variation that isn't fully explained yet: some of the spread between minimal responders and super-responders comes down to genetics and receptor sensitivity researchers are still mapping.

Is a plateau normal, or has it stopped working?

Yes, plateauing is normal, and tirzepatide's own long-duration data shows it happening on a fairly predictable schedule rather than at random. A 2025 analysis of SURMOUNT-1 and SURMOUNT-4 found the median time to reach a weight plateau — defined as less than 5% further change over a 12-week stretch — ran from about six months for people who started at a lower BMI up to about nine months for people who started at a higher one, with higher tirzepatide doses and being female both associated with plateauing somewhat later rather than earlier. By week 72, the large majority of participants — roughly 88% to 90% across BMI groups — had reached that plateau.

A plateau also isn't the same as the drug quietly failing. In SURMOUNT-1's own three-year extension, average weight loss at week 176 was essentially the same as it had been at week 72 — the number held rather than climbing or slipping back. That's a body settling at a new stable weight once the dose has been at its ceiling for a while, the same pattern that shows up after most successful weight-loss methods. What's different from a healthy plateau is weight actively climbing back up on an unchanged dose — that pattern is worth raising with your prescriber sooner rather than later, since it isn't what the trial data describes as normal.

Does the weight come back if you stop tirzepatide?

For most people, yes — a meaningful share of it. SURMOUNT-4 followed people who'd already spent 36 weeks on tirzepatide reaching an average of about 21% weight loss, then randomized them to either keep taking it or switch to placebo for another year. The group that kept taking it lost an additional 6.7% on average. The group that stopped regained an average of about 14% of their body weight over that same year — though they still ended the trial with roughly 10% weight loss overall, well above where they'd started.

That's the honest read of the evidence: tirzepatide treats an ongoing condition the way blood-pressure medication does, not a temporary course of treatment. Stopping doesn't erase every gain, but it does mean the underlying biology reasserts itself to a real degree — worth factoring in before treating the medication as a short-term bridge rather than a longer commitment.

What does this cost, and where do you actually start?

Cost varies enough by brand, dose, and whether insurance recognizes a weight-loss indication that a single number here would be more misleading than useful. Zepbound's on-label status gives it a real shot at insurance coverage and manufacturer savings programs that Mounjaro used off-label for weight loss generally doesn't get; compounded tirzepatide sits in a narrower, shifting regulatory space and is worth understanding before assuming it's the cheaper default. What's consistent across all of it is that comparing real, current pricing before committing saves real money.